Immix Biopharma(US:IMMX) Globenewswireยท2025-11-03 13:45Core Insights - Immix Biopharma, Inc. announced that interim results from its Phase 1/2 NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis will be presented at ASH 2025 [1][2] Industry Overview - AL Amyloidosis is a severe disease characterized by the immune system producing toxic light chains, leading to organ failure and death [3][7] - The U.S. patient population with relapsed/refractory AL Amyloidosis is projected to grow at a rate of 12% annually, reaching approximately 37,270 patients by 2025 [3] - The amyloidosis market was valued at $3.6 billion in 2017 and is expected to grow to $6 billion by 2025 [4] Company Overview - Immix Biopharma is recognized as the global leader in relapsed/refractory AL Amyloidosis, focusing on the development of NXC-201, a CAR-T cell therapy designed to target and eliminate toxic light chains [5][7] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Orphan Drug Designation (ODD) from both the FDA and EMA [5][7] - The NEXICART-2 trial is a multi-site Phase 1/2 clinical study aimed at evaluating NXC-201, with an expected enrollment of 40 patients [6][7]